Udenafil As a Therapeutic Option for Pulmonary Arterial Hypertension

Overview

Journal Korean Circ J

Date 2019 Feb 27

PMID 30808087

Citations 1

Authors

Hyung Yoon Kim

Kye Hun Kim

Affiliations

Soon will be listed here.

Citing Articles

Repurposing of medications for pulmonary arterial hypertension.

Toshner M, Spiekerkoetter E, Bogaard H, Hansmann G, Nikkho S, Prins K Pulm Circ. 2020; 10(4):2045894020941494.

PMID: 33282182 PMC: 7682234. DOI: 10.1177/2045894020941494.

References

Galie N, Ghofrani H, Torbicki A, Barst R, Rubin L, Badesch D . Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353(20):2148-57. DOI: 10.1056/NEJMoa050010. View

Galie N, Brundage B, Ghofrani H, Oudiz R, Simonneau G, Safdar Z . Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119(22):2894-903. DOI: 10.1161/CIRCULATIONAHA.108.839274. View

Benza R, Miller D, Barst R, Badesch D, Frost A, McGoon M . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2):448-456. DOI: 10.1378/chest.11-1460. View

Kang S, Kim J . Udenafil: efficacy and tolerability in the management of erectile dysfunction. Ther Adv Urol. 2013; 5(2):101-10. PMC: 3607490. DOI: 10.1177/1756287212470019. View

Kim K, Kim H, Hwang I, Lee S, Cho H, Kang H . ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial. Trials. 2013; 14:188. PMC: 3694004. DOI: 10.1186/1745-6215-14-188. View

Kreisel W, Deibert P, Kupcinskas L, Sumskiene J, Appenrodt B, Roth S . The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis. 2014; 47(2):144-50. DOI: 10.1016/j.dld.2014.10.018. View

Kim H, Kim Y, Kim K, Lee S, Kim H, Sohn D . Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy. Hypertens Res. 2015; 38(9):597-604. DOI: 10.1038/hr.2015.46. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

Yoon K . New Therapeutic Target for Pulmonary Arterial Hypertension. Korean Circ J. 2018; 48(12):1145-1147. PMC: 6221863. DOI: 10.4070/kcj.2018.0250. View

10.

Chang S, Kim H, Chang H, Kim D . Acute Hemodynamic Changes after Single Administration of Udenafil in Pulmonary Arterial Hypertension: a Phase IIa Study. Korean Circ J. 2019; 49(4):353-360. PMC: 6428952. DOI: 10.4070/kcj.2018.0281. View